The drug, called retatrutide, is being developed by pharmaceutical company Eli Lilly.
The findings were presented at the American Diabetes Association conference in New Orleans.
One of the trials included 2,339 people with obesity. Participants received different doses of the medication over an 80-week period.
Those receiving the highest doses experienced the greatest weight loss.
Also read: The Gut Can Switch Off Your Craving for Sugar, New Study Finds
According to Eli Lilly, some participants lost more than a quarter of their body weight.
Around one in three participants on the highest dose reduced their BMI to below 25.
Known side effects
Researchers also recorded side effects. The most common were nausea, diarrhea, and vomiting.
Some participants also experienced changes in sensation or developed urinary tract infections.
Also read: Experts warn: These everyday foods could be turning your teeth yellow
The drug has not yet been approved and is still being tested in clinical trials.
At the same time, authorities are warning against illegal copies of the medication, which, according to The Sun, are being sold through social media.
More than weight loss
Researchers also examined other health effects.
Another study involving 537 people with type 2 diabetes showed, among other findings, improvements in blood pressure.
Also read: Do you eat at irregular times? Your gut may notice
However, the most striking part of the results came from analyses of obesity-related conditions.
According to Eli Lilly, the severity of sleep apnea was reduced by 60 percent among participants with obesity.
At the same time, pain caused by knee osteoarthritis decreased by up to 73 percent.
The findings therefore suggest that retatrutide may affect several of the diseases that often accompany obesity.
Also read: Are you the oldest, middle, or youngest? Researchers find differences in siblings' intelligence
Sources: The Sun and American Diabetes Association.
Also read: New research: Five minutes of prayer may reduce pain and anxiety
This article is made and published by Ida-Marie Palm Varbæk, who may have used AI in the preparation.